DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1983)

46 Biopharma Reports

  • Dermatology
IL-17 inhibitors have set a new efficacy standard in moderate to severe...
IL-17 inhibitors have set a new efficacy standard in moderate to severe psoriasis, putting pressure on the more established TNF-α inhibitors and the IL-12/23 inhibitor Stelara. Although IL-17 inhib......
IL -17 inhibitors have established a high standard for efficacy in moderate to...
IL -17 inhibitors have established a high standard for efficacy in moderate to severe psoriasis, placing pressure on current therapies that are less efficacious and a great number of investigationa......
The psoriasis market has become increasingly lucrative owing to the growing use...
The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population who cannot be adequately controlled with topical agents. The domina......
1 - 20 of 46